Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Rhea-AI Summary

Priovant (NASDAQ: ROIV) launched a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), enrolling its first subjects in March 2026. LPP affects ~100,000 US adults and lacks FDA-approved treatments. Brepocitinib is already in late-stage development for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.

The FDA granted Priority Review to the DM NDA with a PDUFA target action date in Q3 2026; topline NIU data and a CS Phase 3 start are expected in H2 2026. Brepocitinib is a dual JAK1/TYK2 inhibitor.

Positive

• Phase 2b/3 enrollment began in March 2026
• Established late-stage program across four indications (LPP, DM, NIU, CS)
• FDA granted Priority Review for DM NDA with PDUFA Q3 2026
• Topline NIU data and CS Phase 3 start expected in H2 2026

Negative

• LPP remains investigational; registrational efficacy not yet demonstrated
• Commercial prospects depend on upcoming DM PDUFA and other trial readouts

Key Figures

US LPP prevalence: approximately 100,000 adults LPP trial stage: Phase 2b/3 Late-stage indications: fourth indication +3 more

6 metrics

US LPP prevalence approximately 100,000 adults Estimated number of adults affected by lichen planopilaris in the United States

LPP trial stage Phase 2b/3 Seamless potentially registrational trial of brepocitinib in LPP

Late-stage indications fourth indication LPP becomes the fourth late-stage indication for brepocitinib

First LPP subjects March 2026 First subjects enrolled in Phase 2b/3 brepocitinib LPP trial

PDUFA timing Q3 2026 PDUFA target action date for brepocitinib NDA in dermatomyositis

NIU & CS milestones 2H 2026 Topline Phase 3 NIU data and Phase 3 CS initiation expected

Market Reality Check

Price: $28.33 Vol: Volume 7,016,137 vs 20-da...

normal vol

$28.33 Last Close

Volume Volume 7,016,137 vs 20-day average 6,158,678 shows slightly elevated trading interest ahead of this news. normal

Technical Trading above 200-day MA at 18.82 and about 8.21% below the 52-week high of 30.33, after rising strongly from the 8.73 52-week low.

Peers on Argus

ROIV gained 0.51% while close peers were mixed: MRNA -3.12%, MDGL -0.28%, HALO +...

ROIV gained 0.51% while close peers were mixed: MRNA -3.12%, MDGL -0.28%, HALO +0.40%, VRNA +0.06%, BPMC +0.09%. With no peers in the momentum scanner, the move appears stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Legal settlement & buyback	Positive	+6.0%	Large Moderna settlement and $1B repurchase program announcement.
Mar 03	FDA Priority Review	Positive	-0.9%	FDA acceptance and Priority Review for brepocitinib in dermatomyositis.
Feb 06	Positive Phase 2 data	Positive	+22.1%	Statistically significant Phase 2 BEACON results in cutaneous sarcoidosis.
Feb 06	Data plus earnings	Positive	+22.1%	Positive CS data, NDA submission, and Q3 results including $4.5B cash.
Jan 23	Earnings date notice	Neutral	+0.7%	Announcement of upcoming Q3 2025 results and business update call.

Pattern Detected

Recent Roivant/Priovant news on brepocitinib and corporate developments has mostly seen price moves align with the positive or neutral tone, with one notable divergence on FDA Priority Review.

Recent Company History

Over the last few months, Roivant and Priovant have reported multiple milestones around brepocitinib, including positive Phase 2 CS data, an NDA acceptance with Priority Review in dermatomyositis, and plans for Phase 3 CS initiation in 2026. A major $2.25 billion settlement involving Genevant/Arbutus and Moderna and a $1 billion share repurchase were also announced on Mar 3, 2026. The new LPP Phase 2b/3 program extends this late-stage expansion into another orphan inflammatory indication.

Regulatory & Risk Context

Active S-3 Shelf · $400.0 million

Shelf Active

Active S-3 Shelf Registration 2025-10-03

$400.0 million registered capacity

Roivant has an effective Form S-3ASR shelf dated October 3, 2025, allowing issuance of common shares and other securities, including up to $400.0 million via a Sales Agreement with TD Securities. As of filing, $0 of that capacity had been used, leaving full flexibility for future capital raises alongside an active share repurchase program.

Market Pulse Summary

This announcement extends brepocitinib into a fourth late-stage indication, targeting lichen planopi...

Analysis

This announcement extends brepocitinib into a fourth late-stage indication, targeting lichen planopilaris, which affects approximately 100,000 adults in the U.S. and has no FDA‑approved therapies. It complements ongoing dermatomyositis, NIU, and CS programs, with a PDUFA date in Q3 2026 and further Phase 3 milestones in the second half of 2026. Investors may track enrollment progress, upcoming data readouts, and any use of the existing $400.0 million shelf for funding development.

Key Terms

phase 2b/3, new drug application (nda), priority review, pdufa, +2 more

6 terms

phase 2b/3 medical

"A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP..."

A phase 2b/3 trial is a combined late-stage clinical study that first refines the best dose and measures how well a treatment works (phase 2b) then expands to a larger, definitive test of safety and effectiveness needed for regulatory approval (phase 3). For investors, results from a phase 2b/3 act like a dress rehearsal that turns into opening night: positive, well-controlled outcomes substantially raise the chance of approval and future sales, while failures can sharply reduce a drug’s value.

new drug application (nda) regulatory

"granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM..."

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

priority review regulatory

"The U.S. Food and Drug Administration (FDA) recently granted Priority Review..."

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

pdufa regulatory

"assigned a Prescription Drug User Fee Act (PDUFA) target action date..."

PDUFA, short for the Prescription Drug User Fee Act, is a law that allows drug companies to pay fees to the government to speed up the review process for new medicines. This helps bring important drugs to market more quickly, which can impact their availability and pricing. For investors, PDUFA timelines can influence the timing of a drug’s approval and potential market success.

orphan conditions medical

"developing brepocitinib in highly morbid orphan conditions with limited treatment options..."

Rare medical disorders that affect a very small number of people compared with common diseases. They matter to investors because treatments for these conditions often receive special regulatory incentives—like faster reviews, fee waivers and market exclusivity—which can make developing a drug for a small patient group economically attractive; think of it as serving a tiny, underserved market where a successful product can command higher prices and steadier demand.

jak1/tyk2 inhibition medical

"distinctive mechanistic benefits of dual JAK1/TYK2 inhibition..."

Blocking JAK1 and TYK2 means using a drug to reduce activity of two enzymes that help immune cells receive and act on chemical signals; think of it as turning down two volume knobs that amplify inflammation. For investors, drugs with JAK1/TYK2 inhibition can treat autoimmune and inflammatory diseases and offer commercial opportunity, but they also carry safety and regulatory risks that can affect clinical success and market value.

AI-generated analysis. Not financial advice.

• Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need
• LPP marks the fourth indication in brepocitinib’s expanding late-stage development program
• Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication
• A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026

DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Priovant today announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States. LPP inflammation targets the stem cell-rich bulge region of the hair follicle (the permanent portion responsible for hair growth), resulting in generally irreversible hair loss and permanent scarring. LPP is also associated with other burdensome symptoms, including pain, burning, itching and scaling, and an increased risk of comorbidities such as other autoimmune diseases and skin cancers. There are currently no FDA-approved therapies to treat LPP.

“Lichen planopilaris (LPP) is what my colleagues and I refer to as a ‘trichologic emergency,’” said Dr. Kristen Lo Sicco, Chief of the Skin and Cancer Unit at NYU Langone Health, Board Member of the Scarring Alopecia Foundation, and Associate Professor of Dermatology at the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. “Absent early diagnosis and aggressive intervention, patients experience rapid hair loss that is generally irreversible, leaves permanent scarring, and is often accompanied by erythema, scaling, pain, itching and burning sensations. Untreated LPP also leads to increased risk of skin cancers and other comorbidities. Efficacious FDA-approved treatments are urgently needed.”

Priovant recently began enrolling subjects in a seamless Phase 2b/3 study of brepocitinib in LPP, with the first subjects enrolled in March 2026. This program marks Priovant’s fourth indication in late-stage clinical development, alongside dermatomyositis (DM), non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS). The U.S. Food and Drug Administration (FDA) recently granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM and assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.

“Expanding brepocitinib into lichen planopilaris continues our strategy of developing brepocitinib in highly morbid orphan conditions with limited treatment options and distinctive mechanistic benefits of dual JAK1/TYK2 inhibition,” said Ben Zimmer, Priovant CEO. “Moreover, as we look ahead to our expected product launch in DM in September, we see LPP as a strategic fit into a multi-indication rheum-derm rare disease franchise anchored by DM, with overlapping prescriber bases and thought leaders.”

About Priovant

Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a first-in-class, selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12 and IL-23—with a single, targeted, once-daily oral therapy. Brepocitinib recently generated positive Phase 3 data in dermatomyositis. The New Drug Application for brepocitinib in dermatomyositis is under review at FDA. Brepocitinib is also being evaluated in a Phase 3 program in non-infectious uveitis, a Phase 3 program in cutaneous sarcoidosis beginning in the second half of calendar year 2026, and a Phase 2b/3 program in lichen planopilaris. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.

Contacts:

Stephanie Lee: stephanie.lee@priovant.com

FAQ

What did Priovant (ROIV) announce about brepocitinib in LPP on April 2, 2026?

Priovant announced a seamless Phase 2b/3 trial for brepocitinib in LPP, with first subjects enrolled in March 2026. According to the company, this expands brepocitinib into a fourth late-stage indication targeting a ~100,000-patient US population.

How large is the LPP patient population Priovant (ROIV) cited for brepocitinib development?

Priovant estimates LPP affects approximately 100,000 adults in the United States. According to the company, LPP causes scarring hair loss and currently has no FDA-approved therapies.

What regulatory progress did Priovant (ROIV) report for brepocitinib in dermatomyositis (DM)?

The FDA granted Priority Review for brepocitinib's DM NDA with a PDUFA target action date in Q3 2026. According to the company, this supports an expected product launch in DM in September 2026.

When does Priovant (ROIV) expect key brepocitinib readouts for NIU and CS in 2026?

Priovant expects topline Phase 3 data in non-infectious uveitis and a Phase 3 start in cutaneous sarcoidosis in H2 2026. According to the company, both milestones are projected in the second half of calendar year 2026.

What is the mechanism of action for brepocitinib that Priovant (ROIV) highlights?

Brepocitinib is a dual JAK1/TYK2 inhibitor that targets inflammatory signaling pathways. According to the company, this mechanism provides a rationale for use across multiple rare rheum-derm indications.

What immediate development milestone did Priovant (ROIV) achieve for brepocitinib in LPP?

Priovant enrolled the first subjects into a seamless Phase 2b/3 LPP trial in March 2026. According to the company, initial enrollment marks the transition to a potentially registrational program.